119 related articles for article (PubMed ID: 2544477)
21. Hormone steroid receptor variation after tamoxifen administration in endometrial adenocarcinoma from postmenopausal patients.
Di Fronzo G; Ronchi E; Cappelletti V; Luciani L; Coradini D; Oriana S; Miodini P; Andreola S
Cancer Detect Prev; 1986; 9(3-4):323-30. PubMed ID: 3742507
[TBL] [Abstract][Full Text] [Related]
22. Endocrine manipulation of meningiomas with medroxyprogesterone acetate. Effect of MPA on receptor status of meningioma cytosols.
Markwalder TM; Waelti E; König MP
Surg Neurol; 1987 Jul; 28(1):3-9. PubMed ID: 2954242
[TBL] [Abstract][Full Text] [Related]
23. Steroid receptors and response of ovarian cancer to hormones in vitro.
Grönroos M; Kangas L; Mäenpää J; Vanharanta R; Nieminen AL; Johansson R
Br J Obstet Gynaecol; 1984 May; 91(5):472-8. PubMed ID: 6232944
[TBL] [Abstract][Full Text] [Related]
24. In vitro growth regulation of endometrial carcinoma cells by tamoxifen and medroxyprogesterone acetate.
Grenman SE; Roberts JA; England BG; Grönroos M; Carey TE
Gynecol Oncol; 1988 Jun; 30(2):239-50. PubMed ID: 2967231
[TBL] [Abstract][Full Text] [Related]
25. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma.
Nola M; Jukić S; Ilić-Forko J; Babić D; Uzarević B; Petrovecki M; Suchanek E; Skrablin S; Dotlić S; Marusić M
Gynecol Oncol; 1999 Mar; 72(3):331-6. PubMed ID: 10053103
[TBL] [Abstract][Full Text] [Related]
26. Induction of progesterone receptor with tamoxifen in human breast cancer with special reference to its behavior over time.
Noguchi S; Miyauchi K; Nishizawa Y; Koyama H
Cancer; 1988 Apr; 61(7):1345-9. PubMed ID: 2964264
[TBL] [Abstract][Full Text] [Related]
27. Mechanism of antitumoral activity of medroxyprogesterone acetate for endometrial cancer.
Fujimoto J; Fujita H; Hosoda S; Okada H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Nov; 41(11):1836-40. PubMed ID: 2531782
[TBL] [Abstract][Full Text] [Related]
28. Morphological and biochemical features of a medroxyprogesterone acetate (MPA)-resistant MCF-7 breast cancer cell line.
Gibelli N; Zibera C; Sica G; Carbone M; Pedrazzoli P; Robustelli della Cuna G
Anticancer Res; 1994; 14(1A):37-43. PubMed ID: 7909420
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of tumor angiogenesis activity by medroxyprogesterone acetate in gynecologic malignant tumors.
Fujimoto J; Hosoda S; Fujita H; Okada H
Invasion Metastasis; 1989; 9(5):269-77. PubMed ID: 2475453
[TBL] [Abstract][Full Text] [Related]
30. Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer.
Gundersen S; Kvinnsland S; Lundgren S; Klepp O; Lund E; Børmer O; Høst H
Breast Cancer Res Treat; 1990 Nov; 17(1):45-50. PubMed ID: 2151369
[TBL] [Abstract][Full Text] [Related]
31. Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate.
Buchanan G; Birrell SN; Peters AA; Bianco-Miotto T; Ramsay K; Cops EJ; Yang M; Harris JM; Simila HA; Moore NL; Bentel JM; Ricciardelli C; Horsfall DJ; Butler LM; Tilley WD
Cancer Res; 2005 Sep; 65(18):8487-96. PubMed ID: 16166329
[TBL] [Abstract][Full Text] [Related]
32. Effects on mouse uterus of three antitumoral drugs acting upon estrogen and progesterone receptors directly and through other transduction pathways.
Actis AM; Dorfman VB; Caruso SP; Levin E
Biochem Pharmacol; 1998 Feb; 55(3):273-8. PubMed ID: 9484792
[TBL] [Abstract][Full Text] [Related]
33. Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: a role for TGFbeta1.
Liang Y; Hou M; Kallab AM; Barrett JT; El Etreby F; Schoenlein PV
Int J Oncol; 2003 Aug; 23(2):369-80. PubMed ID: 12851686
[TBL] [Abstract][Full Text] [Related]
34. Steroid hormone receptors and response to high-dose medroxyprogesterone acetate in advanced breast cancer.
Nomura Y; Tashiro H; Hisamatsu K; Shinozuka K
Anticancer Res; 1988; 8(4):647-51. PubMed ID: 2972248
[TBL] [Abstract][Full Text] [Related]
35. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.
Lim YC; Desta Z; Flockhart DA; Skaar TC
Cancer Chemother Pharmacol; 2005 May; 55(5):471-8. PubMed ID: 15685451
[TBL] [Abstract][Full Text] [Related]
36. Effects of prolonged tamoxifen treatment on receptor expression and apoptosis of ovarian cancer cells.
Zhou R; Treeck O; Horn F; Ortmann O
Gynecol Oncol; 2005 Mar; 96(3):678-83. PubMed ID: 15721411
[TBL] [Abstract][Full Text] [Related]
37. [Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors].
Nomura Y; Tashiro H; Hisamatsu K; Toi M
Gan To Kagaku Ryoho; 1988 Mar; 15(3):513-8. PubMed ID: 2964811
[TBL] [Abstract][Full Text] [Related]
38. mRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen.
Revillion F; Pawlowski V; Lhotellier V; Louchez MM; Peyrat JP
Anticancer Res; 2003; 23(2B):1455-60. PubMed ID: 12820409
[TBL] [Abstract][Full Text] [Related]
39. Five novel hormone-responsive cell lines derived from murine mammary ductal carcinomas: in vivo and in vitro effects of estrogens and progestins.
Lanari C; Lüthy I; Lamb CA; Fabris V; Pagano E; Helguero LA; Sanjuan N; Merani S; Molinolo AA
Cancer Res; 2001 Jan; 61(1):293-302. PubMed ID: 11196177
[TBL] [Abstract][Full Text] [Related]
40. Hormone dependency of human breast neoplasms cultured in vitro in the stem cell assay.
Manni A; Wright C; Pontari M; Feil P; Joehl R
J Natl Cancer Inst; 1985 Apr; 74(4):767-70. PubMed ID: 2985856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
